METASTATIC
Clinical trials for METASTATIC explained in plain language.
Never miss a new study
Get alerted when new METASTATIC trials appear
Sign up with your email to follow new studies for METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR-T therapy aims to outsmart Hard-to-Treat solid cancers
Disease control Recruiting nowThis early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…
Matched conditions: METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail aims to outsmart ALK lung cancer
Disease control Recruiting nowThis study tests a combination of two drugs—lorlatinib (a daily pill) and ramucirumab (an IV infusion every three weeks)—in people with advanced ALK-rearranged non-small cell lung cancer. The first part finds the safest dose, and the second part checks if that dose helps keep the…
Matched conditions: METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo aims to wipe out hidden breast cancer cells after standard treatment
Disease control Recruiting nowThis study tests whether adding the drug sarilumab to chemotherapy (capecitabine) can eliminate tiny amounts of cancer left behind after standard treatment in people with triple negative breast cancer, a very aggressive type. The goal is to prevent the cancer from coming back and…
Matched conditions: METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for rare gut cancers: triple-drug combo shows promise
Disease control Recruiting nowThis study tests a combination of three drugs (surufatinib, sintilimab, and capecitabine) in people with advanced small bowel or appendix cancer that has spread and stopped responding to standard treatments. The goal is to see if this mix can shrink tumors or slow cancer growth. …
Matched conditions: METASTATIC
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC